Vioxx Withdrawal Shows Need To “Reconsider” FDA Approval Process – Kessler
This article was originally published in The Pink Sheet Daily
Executive Summary
Former FDA commissioner says agency may “need to be more careful” in its reviews of drugs for less serious conditions during interview broadcast by National Public Radio. “It certainly is a time for reconsideration” of FDA’s approach to drug approvals and post-marketing safety, Kessler says.
You may also be interested in...
U.K. Adverse Events System Will Allow Patients To Submit Reports, Review Data
The Medicines & Healthcare Products Regulatory Agency will have a final system for direct patient reporting of adverse events by 2006, the agency says. MHRA seems to acknowledge the careful balance required to post adverse event data without deterring appropriate drug use.
U.K. Adverse Events System Will Allow Patients To Submit Reports, Review Data
The Medicines & Healthcare Products Regulatory Agency will have a final system for direct patient reporting of adverse events by 2006, the agency says. MHRA seems to acknowledge the careful balance required to post adverse event data without deterring appropriate drug use.
Sen. Grassley Plans Legislation On Independence Of FDA Drug Safety Office
Finance Committee chair acknowledges he does not have enough votes for such legislation but says he is starting the "process of educating my colleagues" and "intends to continue that until we get this job done." Grassley's requested GAO report on the Office of Drug Safety will take several months.